IVIG

What can we help you find?
[[thumbnail_alt_text]]
Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.
[[thumbnail_alt_text]]
A study found that intravenous immune globulin dosing optimization through alternative dosing weights represents a significant source of waste reduction and cost reduction.
[[thumbnail_alt_text]]
In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.
[[thumbnail_alt_text]]
Carefully implemented order sets may encourage evidence-based or institution-specific care though the influence of provider behavior.
[[thumbnail_alt_text]]
Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.
[[thumbnail_alt_text]]
The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.
[[thumbnail_alt_text]]
The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.
[[thumbnail_alt_text]]
IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.
[[thumbnail_alt_text]]
Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.
[[thumbnail_alt_text]]
Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.
[[thumbnail_alt_text]]
Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.
[[thumbnail_alt_text]]
Debilitating and degenerative, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease affecting 1.6 per 100,000 Americans annually.